• About
    • Team
  • Technology
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact

Recent Posts

  • Icosavax Appoints Thomas J. Russo Chief Financial Officer June 10, 2021
  • Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials April 7, 2021
  • Lorem ipsum dolor sit met. August 29, 2016
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer porttitor imperdiet dui. Nam metus libero, iaculis et iaculis sed, suscipit vitae urna. Phasellus in tincidunt felis. August 29, 2016
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. August 29, 2016

Archives

  • June 2021
  • April 2021
  • August 2016
  • July 2016
  • June 2016
  • April 2016
  • February 2016
  • January 2016

Categories

  • Uncategorized
  • Press Releases

Archives

  • June 2021
  • April 2021
  • August 2016
  • July 2016
  • June 2016
  • April 2016
  • February 2016
  • January 2016

BioSpace: Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing

Icosavax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from

Experimental respiratory syncytial virus vaccine prompts antibody surge

Via NIH.gov   A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in

BioSpace: Icosavax’s Nanoparticle VLP-based Vaccine Offers First-in-Class Solution for RSV

BioSpace reporter Gail Dutton reports on Icosavax’s computationally designed virus-like particle (VLP) vaccine platform as a potential first-in-class vaccine for

Icosavax named a top academic spinout by Nature Biotechnology

For Nature Biotechnology’s annual survey, the list of companies represents some of the best science that was spun out from

Computer-designed vaccine elicits potent antibodies to RSV

Via UW Medicine   A first-of-its-kind nanoparticle vaccine candidate for respiratory syncytial virus has been designed in an international research

Icosavax, Inc.
1616 Eastlake Avenue E. Suite 208
Seattle, WA 98102

info@icosavax.com

Sign up for News updates

© 2022 Icosavax, Inc. All Rights Reserved.
  • Privacy policy
  • Terms of Use
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy